Business Context and Reporting Period
Company: CG Oncology, Inc. (CGON)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an oncolytic immunotherapy for bladder cancer. The company has no approved products and relies on clinical trial progress and capital markets for funding.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $1,157 | $0 | $2,240 | $52 |
| Net Loss | $(79,056) | $(41,426) | $(139,258) | $(75,878) |
| Net Loss Per Share (Basic/Diluted) | $(0.90) | $(0.54) | $(1.61) | $(1.00) |
| Cash, Cash Equivalents & Marketable Securities | $1,028,278 (as of June 30, 2026) | |||
| Working Capital | $1,002,407 (as of June 30, 2026) | |||
| Long-Term Debt | $3,000 (Biovire Note) | |||
| Accumulated Deficit | $(518,234) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $1.1 million in commercial and development revenue for Q2 2026, compared to zero in Q2 2025. This is attributable to the consolidation of Biovire, Inc. (a contract manufacturer) following a conversion event in July 2025.
- Operating Expenses: Total operating costs increased by $38.8 million in Q2 2026 compared to Q2 2025.
- R&D Expenses: Increased $23.3 million (Q2) and $39.6 million (6M) primarily due to higher external clinical trial costs (Chemistry, Manufacturing, and Controls) and increased personnel costs.
- G&A Expenses: Increased $11.6 million (Q2) driven by higher compensation costs and stock-based compensation.
- Capital Raise: During the six months ended June 30, 2026, the company raised approximately $391.4 million in net proceeds from a follow-on public offering under its Jefferies Sales Agreement.
- Investing Activities: Net cash used in investing activities increased to $304.4 million (6M 2026) from $185.4 million (6M 2025), driven by significant purchases of marketable securities ($783.4 million).
Outlook, Risks, and Management Commentary
- Clinical Progress: The company reported a 75.5% complete response rate in the BOND-003 Phase 3 trial for high-risk BCG-unresponsive NMIBC. A Biologics License Application (BLA) is expected to be submitted to the FDA in Q4 2026.
- Liquidity: Management believes existing cash and marketable securities ($1.03 billion) are sufficient to fund operations for at least the next 12 months. The company maintains an at-the-market facility to sell up to an additional $500 million of common stock.
- Legal Proceedings: The company successfully defended against a lawsuit by ANI Pharmaceuticals. A jury rejected ANI's claims for unjust enrichment, and the court denied ANI's motions for a new trial. The company will not owe a 5% royalty on future sales of cretostimogene to ANI, though appeals are possible.
- Risks: The company has a history of losses and expects to continue incurring significant expenses. There is no guarantee of regulatory approval or commercial success. Future funding may be required, potentially leading to dilution.
Investor Verification Checklist
- BLA Submission Timeline: Verify the Q4 2026 target for the Biologics License Application submission for cretostimogene.
- Cash Burn Rate: Monitor the quarterly net loss and operating cash burn to assess the runway beyond the stated 12-month liquidity horizon.
- Biovire Integration: Review the impact of the Biovire acquisition on future cost of sales and manufacturing capacity.
- Legal Finality: Confirm the final status of the ANI Pharmaceuticals litigation and any potential appeal outcomes.
- Capital Markets: Track utilization of the Jefferies Sales Agreement and potential dilution from future equity raises.